129 related articles for article (PubMed ID: 1384917)
1. Can serum prostate-specific antigen replace bone scintigraphy in the follow-up of metastatic prostatic cancer?
Sissons GR; Clements R; Peeling WB; Penney MD
Br J Radiol; 1992 Oct; 65(778):861-4. PubMed ID: 1384917
[TBL] [Abstract][Full Text] [Related]
2. The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy.
Begic A; Kucukalic-Selimovic E; Obralic N; Duric O; Lacevic N; Begovic-Hadzimuratovic S; Skopljak A; Dzubur-Aganovic M
Med Arh; 2006; 60(1):54-5. PubMed ID: 16425536
[TBL] [Abstract][Full Text] [Related]
3. Correlation of serum prostate specific antigen levels and bone scintigraphy in carcinoma prostate.
Oommen R; Geethanjali FS; Gopalakrishnan G; Chacko N; John S; Kanagasabapathy AS; Roul RK
Br J Radiol; 1994 May; 67(797):469-71. PubMed ID: 7514940
[TBL] [Abstract][Full Text] [Related]
4. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between pretreatment serum levels of prostate specific antigen and bone metastasis in prostate cancer].
Kageyama Y; Kihara K; Kamata S; Nagahama K; Yonese J; Fukuda H; Tosaka A; Nagamatsu H; Ishizaka K; Tsujii T; Kitahara S; Morita T; Oshima H
Hinyokika Kiyo; 1996 Mar; 42(3):197-9. PubMed ID: 8619388
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen as a marker of bone metastasis in patients with prostate cancer.
Wolff JM; Bares R; Jung PK; Buell U; Jakse G
Urol Int; 1996; 56(3):169-73. PubMed ID: 8860738
[TBL] [Abstract][Full Text] [Related]
7. [Prostate-specific antigen, acid phosphatases and rectal exploration in the diagnosis of prostatic cancer].
Andersen BR; Knorr UB; Brasso K; Iversen P
Ugeskr Laeger; 1997 Apr; 159(17):2538-42. PubMed ID: 9182382
[TBL] [Abstract][Full Text] [Related]
8. Contribution of bone scintigraphy, prostatic acid phosphatase and prostate-specific antigen to the monitoring of prostatic cancer.
Hetherington JW; Siddall JK; Cooper EH
Eur Urol; 1988; 14(1):1-5. PubMed ID: 2449352
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
Barichello M; Gion M; Bonazza A; Delli Ponti US; Bolgan A; Contemori GP; Barioli P; Capitanio G; Pecori B; Omacini S
Eur Urol; 1995; 27(4):295-300. PubMed ID: 7544735
[TBL] [Abstract][Full Text] [Related]
10. A reappraisal of serial isotope bone scans in prostate cancer.
O'Donoghue JM; Rogers E; Grimes H; McCarthy P; Corcoran M; Bredin H; Given HF
Br J Radiol; 1993 Aug; 66(788):672-6. PubMed ID: 7536607
[TBL] [Abstract][Full Text] [Related]
11. [Is it possible to do without bone gammagraphy in the staging of prostatic cancer?].
Ruiz de la Roja JC; Llorente Abarca C; Romero Cagigal I; Páez Borda A; Fernández González I; Martín Osés E; Berenguer Sánchez A
Actas Urol Esp; 1995 Feb; 19(2):123-7. PubMed ID: 7539572
[TBL] [Abstract][Full Text] [Related]
12. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer.
Oesterling JE; Martin SK; Bergstralh EJ; Lowe FC
JAMA; 1993 Jan; 269(1):57-60. PubMed ID: 7677962
[TBL] [Abstract][Full Text] [Related]
13. Association of prostate-specific antigen levels and patterns of benign and malignant uptake detected. on bone scintigraphy in patients with newly diagnosed prostate carcinoma.
Jacobson AF
Nucl Med Commun; 2000 Jul; 21(7):617-22. PubMed ID: 10994663
[TBL] [Abstract][Full Text] [Related]
14. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up.
Freitas JE; Gilvydas R; Ferry JD; Gonzalez JA
J Nucl Med; 1991 Jul; 32(7):1387-90. PubMed ID: 1712383
[TBL] [Abstract][Full Text] [Related]
15. Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy.
Terris MK; Klonecke AS; McDougall IR; Stamey TA
J Nucl Med; 1991 Sep; 32(9):1713-7. PubMed ID: 1715394
[TBL] [Abstract][Full Text] [Related]
16. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
[TBL] [Abstract][Full Text] [Related]
17. [Impact of specific prostatic antigen on the rationalization of the use of bone gammagraphies in the follow-up of hormone-treated non- metastatic prostatic cancer].
Morote Robles J; Reig Ruiz C; Vila Barja J; López Pacios MA; de Torres Mateos JA; Soler Roselló A
Actas Urol Esp; 1993 May; 17(5):292-4. PubMed ID: 7688176
[TBL] [Abstract][Full Text] [Related]
18. Predicting bone scan findings using sPSA in patients newly diagnosed of prostate cancer: feasibility in Asian population.
Lai MH; Luk WH; Chan JC
Urol Oncol; 2011; 29(3):275-9. PubMed ID: 19734069
[TBL] [Abstract][Full Text] [Related]
19. Association between bone scintigraphy and serum levels of procollagen (I) and PSA in the detection of bone disease in prostate cancer patients.
Zissimopoulos A; Bantis A; Stellos K; Petrakis G; Matthaios D
J BUON; 2008; 13(1):69-74. PubMed ID: 18404790
[TBL] [Abstract][Full Text] [Related]
20. [Bone scintigraphy in prostatic cancer. Correlation with clinical and laboratory features and with survival].
Lobo G; Ladrón de Guevara D; Salgado G; Donoso G; Bagus F
Rev Med Chil; 1999 Feb; 127(2):181-8. PubMed ID: 10436698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
